logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Mid 2017
Karyopharm Therapeutics Inc.
Topline data from phase 2 portion of phase 2/3 clinical trial with oral Selinexor (SEAL)
Advanced unresectable dedifferentiated liposarcoma
Mid 2017
Tokai Pharmaceuticals Inc.
Topline data from phase 3 registration clinical of Galeterone (ARMOR3-SV)
Metastatic castration-resistant prostate cancer (mCRPC)
Mid 2017
Karyopharm Therapeutics Inc.
Top-line data from Phase 2 study of Selinexor (SOPRA study)
Older patients with relapsed/refractory acute myeloid leukemia (AML)
Mid 2017
Supernus Pharmaceuticals, Inc.
Data from phase 3 study of SPN-810
Impulsive Aggression in patients who have ADHD
Mid 2017
BioTime Inc
Topline data from pivotal trial of Renevia
Restoring normal skin contours in patients whose adipose tissue has been lost due to antiviral drug treatment for HIV
Mid 2017
Cytori Therapeutics Inc.
Data from phase 3 study of Cytori Cell Therapy (STAR)
Impaired hand function from scleroderma
Mid 2017
GTX Inc.
Top-line data from full Phase 2 study of Enobosarm
Breast cancer
Mid 2017
Alnylam Pharmaceuticals Inc.
Data from phase 3 trial with Patisiran (APOLLO)
Hereditary TTR-mediated amyloidosis with polyneuropathy
Mid 2017
Karyopharm Therapeutics Inc.
Topline data from Phase 2/3 trial of Selinexor (SCORE)
Multiple Myeloma
Mid 2017
Alnylam Pharmaceuticals Inc.
Initial data from phase 1/2 trial of ALN-HBV
Chronic hepatitis B virus
Mid 2017
Clovis Oncology, Inc.
Data from phase 3 pivotal maintenance study of Rucaparib (ARIEL3)
Ovarian cancer
Mid 2017
Arena Pharmaceutical Inc.
Data from phase 2 trial of Ralinepag
pulmonary arterial hypertension
Mid 2017
RedHill Biopharma Ltd.
Topline results from Phase II study with BEKINDA
diarrhea-predominant irritable bowel syndrome (IBS-D)
Mid 2017
Inspyr Therapeutics, Inc.
NSPX.OB
Topline results from phase 2 trial of Mipsagargin
Newly Diagnosed Prostate Cancer
Mid 2017
GW Pharmaceuticals PLC
GWPH, GWP.L
NDA submission for Epidiolex
Dravet syndrome and Lennox-Gastaut Syndrome (LGS)
Mid 2017
Amarin Corp Plc
2nd pre-specified interim efficacy analysis of phase 3 trial of Vascepa (REDUCE-IT)
Cardiovascular outcomes study of Vascepa
Mid 2017
Array BioPharma Inc.
Data from part 2 of phase 3 trial of Binimetinib and Encorafenib (COLUMBUS)
BRAF-mutant advanced melanoma.
Mid 2017
Prothena Corporation plc
Interim analysis of phase Ib study of PRX003
psoriatic arthritis
Mid 2017
Theravance Biopharma Inc.
Data from Phase 1b trial of TD-1473
moderate to severe ulcerative colitis.
Mid 2017
Ardelyx, Inc
Data read-out from phase 3 study of Tenapanor (T3MPO-1)
irritable bowel syndrome with constipation (IBS-C)
Mid 2017
MEI Pharma, Inc.
Interim data from Phase 1b clinical study of ME-401
lymphomas
Mid 2017
RXi Pharmaceuticals Corp.
Complete read-out from phase 2a study of RXI-109-1402
Hypertrophic Scarring
Mid 2017
Marinus Pharmaceuticals
Top-line data from phase 2 trial of Ganaxolone
children with CDKL5 genetic disorder
Mid 2017
AstraZeneca PLC
AZN.L, AZN
PFS data from phase 3 trial of Durvalumab (MYSTIC)
1st-line non-small cell lung cancer
Mid 2017
Xenon Pharmaceuticals Inc.
Data from phase 2b trial of TV-45070
post-herpetic neuralgia